Last reviewed · How we verify

CCB use

GlaxoSmithKline · Phase 2 active Small molecule

CCBs work by inhibiting the L-type calcium channels in the heart and vascular smooth muscle, leading to vasodilation and reduced cardiac workload.

CCBs work by inhibiting the L-type calcium channels in the heart and vascular smooth muscle, leading to vasodilation and reduced cardiac workload. Used for Hypertension, Angina pectoris.

At a glance

Generic nameCCB use
SponsorGlaxoSmithKline
Drug classCalcium channel blocker
TargetL-type calcium channels
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 2

Mechanism of action

This results in decreased peripheral resistance, reduced blood pressure, and a decrease in cardiac workload, which can help alleviate symptoms of hypertension and angina. CCBs can also have a negative inotropic effect, which can be beneficial in certain cardiac conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: